Product Description: MK-2206 is an orally active, highly potent and selective allosteric Akt inhibitor, with IC50s of 8, 12, and 65 nM for Akt1, Akt2, and Akt3, respectively. Many breast cancer cell lines, and PIK3CA-mutant and cell lines with PTEN loss are sensitive to MK-2206. MK-2206 has anticancer activities[1][2].
Applications: Cancer-Kinase/protease
Formula: C25H22ClN5O
Citations: ACS Omega. 2023 Jun 16./Acta Pharmacol Sin. 2023 May 24./Adv Sci (Weinh). 2025 Feb 20:e2408106./Am J Physiol Gastrointest Liver Physiol. 2022 May 31./Antioxidants (Basel). 2022 Oct 18;11(10):2050./Arch Biochem Biophys. 2023 Apr 1;109595./Biochem Biophys Res Commun. 2022./Biochem Biophys Res Commun. 2023 Nov 5, 680, Pages 127-134./Biomed Pharmacother. 2024 Jan:170:116100./bioRxiv. 2023 May 14./bioRxiv. 2024 Feb 8./Blood Adv. 2023 Mar 15;bloodadvances.2022009249./BMC Complement Med Ther. 2023 Oct 10;23(1):358./Bone Res. 2025 Feb 24;13(1):25./Bone. 2021 Oct 12;116231./Brain Res Bull. 2020 Sep;162:166-179./Brain Res Bull. 2023 Mar 15;196:46-58./Cancer Lett. 2023 Jan 18;556:216063./Cancer Lett. 2024 Apr 9:591:216848./Cancers. 2020 Jul 16;12(7):1918./Carbohydr Polym. 2024 Feb 15, 326, 121637./Cell Cycle. 2022 Aug 25;1-12./Cell Death Dis. 2020 May 11;11(5):353. /Cell Death Discov. 2020 Jul 6;6:56./Cell Mol Immunol. 2023 Jan 5./Cell Rep. 2022 Feb 15;38(7):110392./Cell Rep. 2023 Oct 17;42(10):113270./Cell Rep. 2023 Sep 1;42(9):113048./Cell Signal. 2023 Oct 20:110933./Cell Stress Chaperones. 2024 Mar 12:S1355-8145(24)00055-5./Clin Exp Hypertens. 2023 Dec 31;45(1):2208777./Cytotechnology. 2025 Apr;77(2):76./Cytotherapy. 2023 Apr 29;S1465-3249(23)00093-2./Ecotoxicol Environ Saf. 2023 Dec 12:269:115816./Environ Toxicol. 2023 Aug 16./Eur J Pharmacol. 2023 Aug 3;956:175957./Eur J Pharmacol. 2024 Feb 11:968:176418./Exp Mol Med. 2022 Nov 24./Exp Ther Med. 2022 Jun;23(6):413./Exp Ther Med. February 22, 2022./FASEB J. 2023 Feb;37(2):e22744./Hematology. 2023 Dec;28(1):2214465./Hum Reprod. 2024 Nov 1:deae246./Indian J Pharm Sci. 2022./Int Immunopharmacol. 2023 May 7;119:110247./Int J Biochem Cell Biol. 2023 Feb;155:106359./Int J Biol Sci. 2023; 19(1): 204-224./Int J Mol Sci. 2023 Nov 22, 24(23), 16611./iScience. 2023 Apr 13./iScience. 2024 Mar 5;27(4):109358./iScience. 2024 Oct 30;27(12):111290./J Agric Food Chem. 2024 Mar 16./J Biochem. 2024 Aug 8:mvae057./J Biol Chem. 2022 Dec 14;102798./J Biol Chem. 2022 May 13;102030./J Biomed Mater Res A. 2020 Aug 28. /J Cancer. 2023 Mar 27;14(5):784-792./J Ethnopharmacol. 2023 Nov 10:117393./J Exp Clin Cancer Res. 2022 Jan 26;41(1):38./J Exp Clin Cancer Res. 2023 Aug 10;42(1):204./J Nanobiotechnology. 2022 Sep 24;20(1):422./J Pharm Pharmacol. 2024 Jan 18:rgae008./J Transl Med. 2022 Nov 5;20(1):509./J Transl Med. 2024 Sep 27;22(1):867./Life Sci. 2023 Aug 23;122001./MedComm (2020). 2024 Aug 12;5(8):e684./Mol Biol Rep. 2022 Nov 4./Mol Carcinog. 2023 Apr 12./Mol Cell. 2025 Jan 21:S1097-2765(24)01066-9./Mol Med Rep. 2021 Jul;24(1):508./Mol Oncol. 2023 Jan 27./Mol Oncol. 2023 Jul 17./Molecules. 2022 Dec 5;27(23):8568./Nat Aging. 2024 Mar 15./Nat Commun. 2022 Apr 19;13(1):2136./Nat Commun. 2022 Nov 29;13(1):7345./Nat Commun. 2023 Sep 28;14(1):6069./Nat Commun. 2025 Mar 14;16(1):2528./Oncogene. 2020 Oct;39(41):6451-6467./Oncol Lett. 2023 Dec 18./Oxid Med Cell Longev. 2022/Phytomedicine. 2022 Jul;101:154121./Phytomedicine. 2023 Jun 23, 154933./Phytomedicine. 2023 Sep 7, 155074./R Soc Open Sci. 2020 Jul 8;7(7):200635./Research Square Preprint. 2021 Aug./Research Square Preprint. 2023 May 23./Research Square Preprint. 2023 May 3./Research Square Preprint. 2023 Oct 11./Research Square Preprint. 2024 Mar 28./Research Square Print. 2023 Mar 9./Research Square Print. October 11th, 2022./Sci Signal. 2023 May 16;16(785):eade8111./Signal Transduct Target Ther. 2024 Mar 9;9(1):65./Thorac Cancer. 2022 May 10./Toxicol In Vitro. 2023 Sep 20;105698./Transl Res. 2023 Nov 4:S1931-5244(23)00181-0./Transplant Cell Ther. 2023 May 14;S2666-6367(23)01292-7./University of Zürich. Department of Dermatology. 2021 Dec./ACS Omega. 2020 Feb 13;5(7):3709-3716./ACS Omega. 2024 Dec 3;9(50):49739-49748./Acta Otolaryngol. 2021 Dec 28;1-7./Acta Pharm Sin B. 2021 Jan;11(1):71-88./Acta Pharm Sin B. 2021 Jun;11(6):1592-1606./Acta Pharmacol Sin. 2018 Nov;39(11):1787-1796./Adv Sci (Weinh). 2024 Jun 3:e2400023./Adv Sci (Weinh). 2024 May 2:e2306348./Adv Sci (Weinh). 2025 Feb 3:e2411719./Aging. 2020 Jun 12;12(12):11717-11731./Aging. 2021 Apr 11;13(7):10672-10687./Am J Cancer Res. 2021 Apr 15;11(4):1557-1571./Angiogenesis. 2025 Feb 3;28(2):13./Ann Transl Med. 2021 Apr;9(7):533./Bioact Mater. 2022 Mar 24;18:116-127./Biochem Biophys Res Commun. 2017 Aug 5;489(4):484-489./Biochem Biophys Res Commun. 2020 Dec 12;534:121-127./Biochem Biophys Res Commun. 2022 Jun 25;610:170-175./Biochem Biophys Res Commun. 2024 Jun 1:723:150200./Biochem Biophys Res Commun. 2025 Jan 16:749:151352./Biochem Biophys Res Commun. 3 October 2022./Biochem Biophys Res Commun. 2019 Feb 26;510(1):97-103. /Biochim Biophys Acta Mol Basis Dis. 2024 Mar 2;1870(4):167111./Biochim Biophys Acta Mol Basis Dis. 2024 Sep 3:167496./Biol Trace Elem Res. 2022 Mar 21./Biomaterials. 2024 Oct:310:122634./Biomed Pharmacother. 2019 Dec;120:109498./Biomed Pharmacother. 2021, 111089./bioRxiv. 2020 Jul 15./bioRxiv. 2020 Mar./bioRxiv. 2024 August 26./bioRxiv. 2024 June 03./bioRxiv. 2025 Feb 1:2025.01.30.635746./Biosci Rep. 2019 Dec 20;39(12):BSR20191041./BMC Cancer. 2024 Oct 7;24(1):1236./Bosn J Basic Med Sci. 2021 Aug 1;21(4):434-446./Br J Cancer. 2017 Sep 26;117(7):974-983./Brain Dev. 2023 Nov 15:S0387-7604(23)00171-7./Cancer Biol Ther. 2022 Jan 9;1-14./Cancer Biol Ther. 2025 Dec;26(1):2442556./Cancer Cell Int. 2021 Apr 26;21(1):235./Cancer Cell Int. 2022 Jan 11;22(1):18./Cancer Cell. 2018 Jun 11;33(6):1061-1077.e6. /Cancer Lett. 2020 Apr 10;475:53-64./Cancer Lett. 2021 Apr 21;S0304-3835(21)00172-5./Cancer Lett. 2022 Jul 12;215826./Cancer Lett. 2024 Jul 31:217147./Cancer Res. 2021 Mar 8;canres.3232.2020./Cancer Sci. 2018 Apr;109(4):944-955. /Cancers (Basel). 2023 Dec, 15(24), 5805./Cell Commun Signal. 2024 Jun 10;22(1):318./Cell Death Differ. 2021 Mar;28(3):1026-1040./Cell Death Differ. 2023 Jan 13./Cell Death Dis. 2018 Oct 3;9(10):1015. /Cell Death Dis. 2019 May; 10(5): 329./Cell Death Dis. 2022 Apr 19;13(4):370./Cell Death Dis. 2022 Sep 29;13(9):838./Cell Death Dis. 2019 Aug 13;10(8):609. /Cell Death Discov. 2024 Jul 19;10(1):329./Cell Immunol. 11 January 2022, 104475./Cell Mol Gastroenterol Hepatol. 2021;11(3):683-696./Cell Oncol. 2021 Jul 28./Cell Prolif. 2021 May 5;e13045./Cell Rep. 2022 Dec 27;41(13):111891./Cell Rep. 2023, 42(1): 111916./Cell Reprogram. 2021 Oct 22./Cell Signal. 2020 Dec 25;109900./Cell Stem Cell. 2019 Dec 5;25(6):754-767.e9. /Cell Syst. 2020 Jan 22;10(1):66-81.e11. /Cell. 2014 Feb 13;156(4):771-85./Cells. 2022 Nov 5;11(21):3505./Chem Biol. 2012 Jan 27;19(1):140-54./Clin Epigenetics. 2018 May 23;10:69./Clin Exp Pharmacol Physiol. 2024 Apr;51(4):e13846./Clin Exp Pharmacol Physiol. 2019 Sep;46(9):861-871./Commun Biol. 2024 Nov 7;7(1):1459./Curr Issues Mol Biol. 2024 Dec 31./Curr Med Sci. 2022 Apr;42(2):387-396./Cytokine. 2020 May;129:155046./Department of Dental Pharmacology. Okayama University. 2015./Department of Laboratory Medicine, Laboratory of Hematology of the Radboudumc and Radboud Institute for Molecular Life Sciences in Nijmegen, The Netherlands.2019 Oct./Dev Growth Differ. 2016 Apr;58(3):280-92./Development. 2024 Sep 30:dev.202899./Ecotoxicol Environ Saf. 2024 Jul 30:283:116804./Elife. 2021 Jul 13;10:e66942./Endocr Relat Cancer. 2019 Aug;26(8):699-712. /Eur J Cancer. 2022 May 19;170:91-102./Eur J Pharmacol. 2019 May 15;851:69-79. /Exp Cell Res. 2020 Dec 1;397(1):112341./Exp Eye Res. 2018 Jul;172:10-20./Exp Ther Med. 2019 May;17(5):3530-3538. /Exp Ther Med. July 29, 2021./FASEB J. 2020 Jan;34(1):1481-1496./FEBS J. 2019 Apr;286(7):1305-1318./FEBS Open Bio. 2021 May 1./Food Chem Toxicol. 2018 Oct;120:500-509./Food Funct. 2021 Mar 9./Free Radic Biol Med. 2022 Oct 19;S0891-5849(22)00930-3./Front Cardiovasc Med. 2021 Sep 3;8:687540./Front Cell Dev Biol. 2021 Apr 14;9:649277./Front Microbiol. 12 September 2022./Front Mol Biosci. 08 July 2021./Genes Dis. 2021 Aug 17;9(2):562-575./Graduate School of Arts & Sciences. Harvard University. 2016 Aug./Harvard Medical School LINCS LIBRARY/Heliyon. 2024 Aug 10;10(16):e36017./Heliyon. 2024 Oct 11;10(21):e39333./Hum Mol Genet. 2017 Sep 15;26(18):3553-3563./In Vitro Cell Dev Biol Anim. 2021 Oct 28./Int Immunopharmacol. 2021 Jan 30;93:107395./Int Immunopharmacol. 2021 Oct 26;101(Pt A):108264./Int Immunopharmacol. 2024 Jul 19:139:112704./Int Immunopharmacol. 2024 Oct 16;143(Pt 2):113399./Int Immunopharmacol. 2024 Sep 18;142(Pt B):113186./Int J Biochem Cell Biol. 2018 Apr;97:16-27./Int J Biochem Cell Biol. 2018 Jun;99:43-51. /Int J Biol Macromol. 2024 Aug 26:135109./Int J Biol Macromol. 2024 Nov 27:138168./Int J Biol Macromol. 2024 Oct 30:137070./Int J Biol Sci. 2021 Apr 24;17(7):1821-1836./Int J Biol Sci. 2024 Oct 14;20(14):5548-5575./Int J Clin Exp Med. 2016;9(9):18513-18518./Int J Clin Exp Pathol. 2017;10(3):3033-3042./Int J Endocrinol. 2024 Nov 12:2024:3494652./Int J Med Sci. 2025 Jan 1;22(1):209-226./Int J Mol Sci. 2022 Aug 8;23(15):8798./Int J Mol Sci. 2023 Jul 6, 24(13), 11168./Int J Oncol. 2017 Aug;51(2):625-632. /iScience. 2021 Sep 25;24(10):103173./J Agric Food Chem. 2022 Feb 1./J Agric Food Chem. 2019 Sep 4;67(35):9805-9811./J Biochem Mol Toxicol. 2019 Nov;33(11):e22391./J Biol Chem. 2012 Mar 23;287(13):9742-52./J Biomed Sci. 2025 Jan 6;32(1):5./J Cancer. 2018 Jun 14;9(14):2480-2491. /J Cell Biochem. 2018 May;119(5):3885-3891./J Cell Biochem. 2019 Oct;120(10):17744-17756./J Cell Biol. 2021 Oct 4;220(10):e202010118./J Cell Mol Med. 2020 Jun;24(12):6869-6882./J Cell Mol Med. 2021 Sep 30./J Cell Mol Med. 2024 Apr;28(7):e18193./J Cell Mol Med. 2024 Apr;28(8):1-11./J Cell Mol Med. 2025 Jan;29(1):e70332./J Cell Mol Med. 2025 Jan;29(2):e70352./J Cell Physiol. 2021 Aug;236(8):5818-5831./J Ethnopharmacol. 2021, 114224./J Ethnopharmacol. 2024 Sep 13:118829./J Ethnopharmacol. 24 December 2021, 114937./J Exp Clin Cancer Res. 2021 Aug 20;40(1):262./J Exp Clin Cancer Res. 2021 Dec 10;40(1):390./J Exp Clin Cancer Res. 2018 Apr 3;37(1):77. /J Exp Clin Cancer Res. 2019 Feb 13;38(1):76./J Hepatocell Carcinoma. 2024 Sep 18:11:1763-1775./J Immunol. 2020 Oct 15;205(8):2255-2264./J Integr Neurosci. 2024 Jan 16, 23(1), 14./J Invest Dermatol. 2019 Jan;139(1):71-80./J Lipid Res. 2024 Nov 15:100701./J Mater Sci Technol. 13 August 2022./J Mol Histol. 2019 Aug;50(4):369-374. /J Neuroinflammation. 2023 Feb 24;20(1):49./J Neuroinflammation. 2024 Aug 2;21(1):192./J Pain Res. 2020 Dec 1;13:3195-3206./J Reprod Immunol. 2023 Mar 5;157:103928./J Transl Med. 2022 Jul 21;20(1):325./J Transl Med. 2023 Feb 3;21(1):74./J Transl Med. 2024 May 14;22(1):457./Lab Invest. 2024 Nov 28:102202./Leuk Res. 2024 Jul 7:144:107548./Life Sci Alliance. 2022 Jun 2;5(10):e202101330./Life Sci. 2020 Mar 15;245:117328./Life Sci. 2020 May 15;249:117503./Life Sci. 2020 Nov 1;260:118470./Life Sci. 2022 Aug 26;120907./Lipids Health Dis. 2024 Dec 27;23(1):424./Mediat Inflamm. 2019 Oct 7;2019:6168340./Microbes Infect. 2025 Feb 18:105481./Microvasc Res. 2024 Apr 16:104689./Modern Oncology. 2017,25(01):0009-0013./Mol Biol Rep. 2021 Nov 3./Mol Cancer Res. 2024 Mar 15./Mol Cancer Ther. 2024 Jun 19./Mol Cancer. 2019 Nov 21;18(1):167. /Mol Carcinog. 2024 Jul 17./Mol Carcinog. 2024 Nov 6./Mol Cell Biochem. 2023 Sep 22./Mol Cell. 2021 Jan 21;81(2):370-385.e7./Mol Cell. 2022 May 13;S1097-2765(22)00393-8./Mol Med Rep. 2022 Jan;25(1):17./Mol Med Rep. 2024 Dec;30(6):213./Mol Metab. 2024 Sep 19:102032./Mol Oncol. 2022 Jul 19./Mol Pharmacol. 2019 Dec;96(6):862-870./Mol Ther Nucleic Acids. 20 July 2022./Mol Ther Nucleic Acids. May 20, 2022./Mol Cancer Res. 2020 Mar;18(3):414-423./Nat Cancer. 2024 May 30./Nat Chem Biol. 2017 Jan;13(1):38-45./Nat Commun. 2018 May 8;9(1):1816. /Nat Commun. 2020 Apr 14;11(1):1792./Nat Commun. 2021 Jun 30;12(1):4050./Nat Commun. 2022 Aug 2;13(1):4495./Nat Commun. 2024 Jun 17;15(1):5144./Nat Commun. 2024 Sep 6;15(1):7791./Nat Struct Mol Biol. 2025 Jan 17./Nature. 2018 Aug;560(7719):499-503./Neurobiol Dis. 2019 Apr;124:520-530./Nutrients. 2022, 14(16), 3395./Oncogene. 2017 Aug 10;36(32):4585-4596./Oncogene. 2018 Nov;37(45):5997-6009. /Oncogene. 2019 Jun;38(26):5250-5264./Oncoimmunology. 2018 Aug 6;7(10):e1488565. /Oncol Lett. 2020 Dec;20(6):398./Oncol Rep. 2019 Aug;42(2):849-856. /Oncol Res. 2024 Nov 13;32(12):1867-1879./Oncotarget. 2016 May 17;7(20):29131-42. /Oncotarget. 2017 Jan 31;8(5):8536-8549. /Oncotarget. 2017 Jul 18;8(29):47642-47654. /Patent. US20140309249A1./Patent. US20160368910A1./Patent. US20190248778A1./Patent. US20210236501A1./Patent. US20220288067A1./PeerJ. October 25, 2022./Peptides. 2018 Sep;107:39-44. /Phytomedicine. 2023 Apr 26;115:154833./Phytomedicine. 2024 Jun 27:132:155846./Phytomedicine. 23 August 2021, 153687./Platelets. 2023 Feb 22;2173505./PLoS One. 2016 Jan 28;11(1):e0147682. /PNAS Nexus. 2024 Aug 13;3(8):pgae321./Proc Natl Acad Sci U S A. 2016 Jul 26;113(30):E4338-47. /Proc Natl Acad Sci U S A. 2019 Feb 19;116(8):2996-3005. /Radiat Res. 2018 Aug;190(2):204-215. /Redox Biol. 2021 Dec 18;49:102217./Reproduction. 2022 Feb 1;REP-21-0282./Research Square Preprint. 2020 Nov./Research Square Preprint. 2022 Feb./Research Square Preprint. 2023 May 5./Research Square Print. August 22nd, 2022./Ruperto Carola University Heidelberg. 2023 Jun 1./Sci Adv. 2022 Jan 21;8(3):eabh2635./Sci Adv. 2024 Dec 13;10(50):eadq4274./Sci Rep. 2020 May 7;10(1):7714./Sci Rep. 2022 Aug 13;12(1):13796./Sci Rep. 2024 Dec 30;14(1):31935./Sci Rep. 2024 Jun 24;14(1):14552./Sci Rep. 2025 Mar 3;15(1):7448./Sci Rep. 2018 Oct 18;8(1):15454/Sci Total Environ. 2021 Nov 10;794:148732./Sci Total Environ. 2024 May 22:935:173456./Sci Transl Med. 2018 Jul 18;10(450):eaaq1093./Science. 2022 Jul 8;377(6602):eabg9302./Shock. 2023 Jul 1;60(1):100-109./Signal Transduct Target Ther. 2021 Jun 18;6(1):234./SSRN. 2024/Stem Cell Res Ther. 2021 Jan 26;12(1):88./Stem Cell Res Ther. 2022 Jan 10;13(1):13./Stem Cell Res Ther. 2025 Feb 28;16(1):100./Stem Cells. 2019 Dec;37(12):1567-1580./Theranostics. 2020 Aug 6;10(21):9899-9912./Theranostics. 2020 Feb 3;10(6):2859-2871./Theranostics. 2021 Jan 19;11(7):3392-3416./Theranostics. 2024 Jul 22;14(11):4481-4498./Theranostics. 2024 Jun 17;14(10):3793-3809./Theranostics. 2018 Feb 15;8(7):2044-2060. /Toxicol Appl Pharmacol. 2022 Mar 5;115969./Toxicology. 2022 Oct;480:153326./Transl Oncol. 2024 Oct 7:50:102146./Virology. 2022 Sep 26;576:83-95.
References: [1]Xing Y, et al. Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation. Breast Cancer Res. 2019 Jul 5;21(1):78./[2]Zhao YY, et al. Effects of an oral allosteric AKT inhibitor (MK-2206) on human nasopharyngeal cancer in vitro and in vivo. Drug Des Devel Ther. 2014 Oct 10;8:1827-37./[3]Agarwal E, et al. Akt inhibitor MK-2206 promotes anti-tumor activity and cell death by modulation of AIF and Ezrin in colorectal cancer. BMC Cancer. 2014 Mar 1;14:145./[4]Li Yan, et al. Abstract #DDT01-1: MK-2206: A potent oral allosteric AKT inhibitor. 2009.
CAS Number: 1032349-77-1
Molecular Weight: 443.93
Compound Purity: 99.72
Research Area: Cancer
Solubility: DMSO : 100 mg/mL (ultrasonic)
Target: Akt;Apoptosis;Autophagy;Organoid
English
Deutsch
